<DOC>
	<DOCNO>NCT02532413</DOCNO>
	<brief_summary>The purpose study investigate antiviral efficacy combination treatment Poly IC Entecavir compare efficacy Entecavir mono-therapy chronic hepatitis B .</brief_summary>
	<brief_title>Antiviral Efficacy Combination Treatment With Poly IC Entecavir Chronic Hepatitis B</brief_title>
	<detailed_description>In study , patient chronic HBV infection divide two group : HBeAg ( + ) HBeAg ( - ) group . Each group divide two subgroup , treat combination treatment Entecavir Poly IC Entecavir monotherapy respectively . All patient follow one year . From study , investigator want study Poly IC enhance antiviral efficacy Entecavir chronic hepatitis B .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<criteria>HBsAg positive 6 month . Having treat wit Entecavir level HBV DNA 1000 copies/ml . ALT ≤10×ULN， TB ＜2ULN . Previous antiviral treatment HBV . Co infection HIV , HCV , HEV , HAV , HAV . Evidence hepatic carcinoma . Evidence autoimmune disease . Evidence thyroid disease . History mental sickness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>